| Title |
Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes
|
|---|---|
| Published in |
Journal of Neuro-Oncology, August 2018
|
| DOI | 10.1007/s11060-018-2966-6 |
| Pubmed ID | |
| Authors |
Zixuan Yuan, Liang Zhao, Yafei Zhang, Shun Li, Bomin Pan, Lei Hua, Zhen Wang, Chengkun Ye, Jun Lu, Rutong Yu, Hongmei Liu |
| Abstract |
GOLPH3 has been shown to be involved in glioma proliferation. In this study, we aimed to demonstrate that GOLPH3 can serve as a target for glioma gene therapy. During the experiment, cationic liposomes with angiopep-2 (A2-CL) were used to deliver siGOLPH3 crossing the blood-brain barrier and reaching the glioma. At the cellular level, the A2-CL/siGOLPH3 could silence GOLPH3 and then effectively inhibited the proliferation of cells. In vivo experiments, using U87-GFP-Luci-bearing BALB/c mouse models, we demonstrated that A2-CL could deliver GOLPH3-siRNA specifically to glioma and effectively inhibit glioma growth. This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 43% |
| United Kingdom | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 43% |
| Science communicators (journalists, bloggers, editors) | 3 | 43% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 28% |
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Professor | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 10 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Neuroscience | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Chemical Engineering | 2 | 7% |
| Chemistry | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 14 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2022.
All research outputs
#4,616,040
of 23,548,905 outputs
Outputs from Journal of Neuro-Oncology
#443
of 3,040 outputs
Outputs of similar age
#86,731
of 331,851 outputs
Outputs of similar age from Journal of Neuro-Oncology
#7
of 66 outputs
Altmetric has tracked 23,548,905 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,040 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,851 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.